BMAA
Alternative Names: BMAA - Chiome Bioscience; Humanized anti-Semphorin3A antibody - Chiome Bioscience; SEMA3A mAbLatest Information Update: 18 Nov 2022
At a glance
- Originator Chiome Bioscience
- Developer Chiome Bioscience; SemaThera
- Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Semaphorin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical CNS disorders; Eye disorders; Inflammation
- No development reported Diabetic macular oedema
Most Recent Events
- 10 Oct 2022 Preclinical trials in CNS disorders in Japan (Parenteral) (Chiome Bioscience pipeline, October 2022)
- 10 Oct 2022 Preclinical trials in Eye disorders in Japan (Parenteral) (Chiome Bioscience pipeline, October 2022)
- 10 Oct 2022 Preclinical trials in Inflammation in Japan (Parenteral) (Chiome Bioscience pipeline, October 2022)